BR112015013762A2 - derivados de tiazol como inibidores de tirosina cinase de bruton - Google Patents

derivados de tiazol como inibidores de tirosina cinase de bruton

Info

Publication number
BR112015013762A2
BR112015013762A2 BR112015013762A BR112015013762A BR112015013762A2 BR 112015013762 A2 BR112015013762 A2 BR 112015013762A2 BR 112015013762 A BR112015013762 A BR 112015013762A BR 112015013762 A BR112015013762 A BR 112015013762A BR 112015013762 A2 BR112015013762 A2 BR 112015013762A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitors
thiazole derivatives
compounds
bruton tyrosine
Prior art date
Application number
BR112015013762A
Other languages
English (en)
Inventor
Javier Lopez-Tapia Francisco
John Silvester Huby Nicholas
So Sung-Sau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015013762A2 publication Critical patent/BR112015013762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

1/1 resumo derivados de tiazol como inibidores de tirosina cinase de bruton esse pedido revela compostos de acordo com a fórmula genérica i: em que todas as variáveis são definidas como descrito aqui, que inibem btk. os compostos revelados aqui são úteis para modular a atividade de btk e tratar doenças associadas à atividade excessiva de btk. os compostos são adicionalmente úteis para tratar doenças inflamatórias e autoimunes associadas a proliferação aberrante de célula-b como artrite reumatóide. são também reveladas composições contendo compostos da fórmula i e pelo menos um veículo, diluente ou excipiente.
BR112015013762A 2012-12-13 2013-12-09 derivados de tiazol como inibidores de tirosina cinase de bruton BR112015013762A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736631P 2012-12-13 2012-12-13
PCT/EP2013/075887 WO2014090715A1 (en) 2012-12-13 2013-12-09 Thiazole derivatives as inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
BR112015013762A2 true BR112015013762A2 (pt) 2017-07-11

Family

ID=49765484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013762A BR112015013762A2 (pt) 2012-12-13 2013-12-09 derivados de tiazol como inibidores de tirosina cinase de bruton

Country Status (12)

Country Link
US (1) US9359345B2 (pt)
EP (1) EP2931721B1 (pt)
JP (1) JP6154482B2 (pt)
KR (1) KR101707761B1 (pt)
CN (1) CN104837837B (pt)
BR (1) BR112015013762A2 (pt)
CA (1) CA2893637A1 (pt)
ES (1) ES2607635T3 (pt)
HK (1) HK1212975A1 (pt)
MX (1) MX2015007291A (pt)
RU (1) RU2015126293A (pt)
WO (1) WO2014090715A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106146A1 (en) * 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3492454A1 (en) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
EP3717459A1 (en) * 2017-11-30 2020-10-07 Step Pharma S.A.S. Compounds
JP7084586B2 (ja) 2018-01-15 2022-06-15 国立研究開発法人産業技術総合研究所 単結晶ダイヤモンド基板を含む積層体
US20220402881A1 (en) * 2019-11-06 2022-12-22 Albert Einstein College Of Medicine Small molecule prostagladin transport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278969B1 (en) * 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors

Also Published As

Publication number Publication date
CA2893637A1 (en) 2014-06-19
JP2016502988A (ja) 2016-02-01
EP2931721B1 (en) 2016-10-26
EP2931721A1 (en) 2015-10-21
CN104837837B (zh) 2017-04-05
RU2015126293A (ru) 2017-01-19
KR101707761B1 (ko) 2017-02-16
HK1212975A1 (zh) 2016-06-24
JP6154482B2 (ja) 2017-06-28
US20150353534A1 (en) 2015-12-10
WO2014090715A1 (en) 2014-06-19
US9359345B2 (en) 2016-06-07
CN104837837A (zh) 2015-08-12
ES2607635T3 (es) 2017-04-03
MX2015007291A (es) 2015-09-10
KR20150093238A (ko) 2015-08-17

Similar Documents

Publication Publication Date Title
BR112015010693A2 (pt) inibidores de tirosina quinase de bruton
BR112013003114A2 (pt) inibidores de tirosina quinase de bruton
BR112014003582A2 (pt) inibidores da tirosina quinase de bruton
BR112014013582A2 (pt) inibidores de quinase de tirosina de bruton
BR112015007513A2 (pt) inibidores de tirosina quinase de bruton
BR112015021806A2 (pt) inibidores de tirosina cinase de bruton
MX345170B (es) Inhibidores de la tirosina-cinasa de bruton.
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
BR112012024117A2 (pt) inibidores de pirrolopirazina quinase
BR112015021677A2 (pt) inibidores de tirosina quinase de bruton
BR112018007381A2 (pt) compostos úteis como imunomoduladores
MX339583B (es) Inhibidores de tirosina cinasa de bruton.
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112015032664A2 (pt) composições
BR112015013762A2 (pt) derivados de tiazol como inibidores de tirosina cinase de bruton
BR112015032595A2 (pt) inibidores de ido
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BR112016022069A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112017023780A2 (pt) sulfonas tricíclicas como moduladores de rorgama

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.